BRADLEY SAENGER - 05 Feb 2025 Form 4 Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)

Role
Chief Financial Officer
Signature
/s/ Bradley Saenger
Issuer symbol
TNXP
Transactions as of
05 Feb 2025
Net transactions value
$0
Form type
4
Filing time
27 Feb 2025, 18:51:04 UTC
Previous filing
29 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TNXP Common Stock, par value $0.001 Other $0 -0 -100% $0.000000 0 05 Feb 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNXP Stock Option Award $0 +25,792 $0.000000 25,792 25 Feb 2025 Common Stock 25,792 $8.05 Direct F2, F3
transaction TNXP Stock Option Award $0 +25,792 $0.000000 25,792 25 Feb 2025 Common Stock 25,792 $10.06 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were surrendered without considerations following a reverse stock split of the Issuer's common stock.
F2 One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
F3 The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.